Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2270780 | 1.00 | TLR4 (0.38) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL7746227 | 1.00 | TLR4 (0.38) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL2270772 | 1.00 | TLR4 (0.38) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL7746236 | 1.00 | TLR4 (0.38) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL2885681 | 1.00 | TLR4 (0.38) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL7746238 | 1.00 | TLR4 (0.38) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL8488915 | 0.94 | CYP2C9 (0.36) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL1300087 | 0.94 | CYP2C9 (0.36) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL10832530 | 0.91 | CYP2C9 (0.35) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL10832533 | 0.91 | CYP2C9 (0.35) | TLR4CYP2C9ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110804444-A | Environment-friendly synthesis method of trans-4-substituted cyclohexyl olefin liquid crystal | 西安瑞联新材料股份有限公司 | 2020-02-18 | — | — | CN | disclosed |
| EP-2020407-B1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | JNC CORP (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-7999123-B2 | 2-oxetanone derivative and process for production thereof | JNC CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-2020407-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | Chisso Corporation (JP) | 2009-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | OGDH, OXGR1, OXER1 | TLR4 2044/4885CYP2C9 88/4885ALDH1A1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.